CN1509753A - Chinese medicine for atrophic vaginitis and premature ovarian failure and its use - Google Patents
Chinese medicine for atrophic vaginitis and premature ovarian failure and its use Download PDFInfo
- Publication number
- CN1509753A CN1509753A CNA021588597A CN02158859A CN1509753A CN 1509753 A CN1509753 A CN 1509753A CN A021588597 A CNA021588597 A CN A021588597A CN 02158859 A CN02158859 A CN 02158859A CN 1509753 A CN1509753 A CN 1509753A
- Authority
- CN
- China
- Prior art keywords
- treatment
- women
- atrophic vaginitis
- ovarian failure
- premature ovarian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 title claims abstract description 13
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 title claims abstract description 13
- 208000004746 Atrophic Vaginitis Diseases 0.000 title claims abstract description 11
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 title claims description 7
- 206010036601 premature menopause Diseases 0.000 title claims description 7
- 208000017942 premature ovarian failure 1 Diseases 0.000 title claims description 7
- 241000208340 Araliaceae Species 0.000 claims abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims description 7
- 230000001568 sexual effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000008350 Pruritus Vulvae Diseases 0.000 claims description 4
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 2
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- -1 through granulation Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese patent medicine for treating atrophic vaginitis and early hypo-ovaria is prepared from 7 Chinese-medicinal materials including dodder seed, phellodendron bark, ginseng, etc.
Description
Technical field:
The invention belongs to medical technical field.
Background technology:
Atrophic vaginitis is one of common disease of climacteric women, has 30% this disease can take place approximately in China's postmenopausal women, abroad reports up to 98.5%.Also can occur in bilateral ovaries excision, irradiation castration or age of sucking long women.It is dry and astringent, scorching hot to suffer from this sick patient Chang Yin pudendum, pruritus vulvae, sexual intercourse discomfort, pain, easily concurrent infection and worried uneasy repeatedly.Atrophic vaginitis is because estrogen level lacks, the vagina resistance reduces, the colpitis due to the bacterial invasion.Estrogen can make vaginal epithelial cell growth, growth, ripe, differentiation, thereby the epithelium holostrome is thickened, and is the most obvious with middle level and top layer especially.Doctor trained in Western medicine mainly adopts estrin treatment and local anti-inflammatory treatment, and common method is smeared vulvovaginal, diethyl stilbestrol sheet plug vagina or oral estrogen as 0.1% diethyl stilbestrol ointment; Local antibiotic medicine mostly is the antibiotic vaginal suppository greatly.But the vagina absorption test is found, estrin treatment need emit certain risk, such as bringing out breast carcinoma, vaginal hemorrhage after menopause or the like, and drawbacks such as the suppository external still has, and dosage is inaccurate, the administration trouble is difficult for adhering to are so western medicine and medical practitioners is also in the practical ground effective way of seeking the treatment atrophic vaginitis.
Summary of the invention:
Problem to be solved by this invention is:
A kind of, pruritus vulvae dry and astringent, scorching hot at postmenopausal women's pudendum is provided, sexual intercourse discomfort, pain, concurrent infection is a kind of Chinese patent medicine preparation and application thereof for the treatment of women's atrophic vaginitis, premature ovarian failure of primary symptom repeatedly.
Medicine of the present invention is made by following component: (consumption is a weight portion)
Semen Cuscutae 80-86
Cortex Phellodendri 80-86
Radix Ginseng 47-53
Cortex Ailanthi 56-66
Rhizoma Anemarrhenae 45-55
Herba Polygoni Avicularis 50-60
Radix Achyranthis Bidentatae 30-36
Formula optimization weight (part) ratio range of medicine of the present invention is:
Semen Cuscutae 82-84
Cortex Phellodendri 82-84
Radix Ginseng 49-51
Cortex Ailanthi 59-61
Rhizoma Anemarrhenae 49-51
Herba Polygoni Avicularis 54-56
Radix Achyranthis Bidentatae 32-34
Range of application of the present invention is:
Dry and astringent, scorching hot, the pruritus vulvae of treatment postmenopausal women's pudendum, sexual intercourse discomfort, pain, concurrent infection repeatedly.
With tcm theory, this prescription is a monarch drug with Semen Cuscutae, Cortex Phellodendri, and the Semen Cuscutae nourishing the liver and kidney is to consolidate it, and Cortex Phellodendri heat clearing and damp drying clearing away damp-heat from lower-JIAO, and Cortex Phellodendri bitterness consolidating YIN make the hard difficulty of coagulating of kidney water that the anxiety of sewing be arranged; Radix Ginseng, Cortex Ailanthi, the Rhizoma Anemarrhenae, Herba Polygoni Avicularis are all ministerial drug, the ginseng qi-tonifying hemopoietic, help lean Tianjin; Cortex Ailanthi heat extraction dampness is with leukorrhagia stopping; The Rhizoma Anemarrhenae rushes down asthenic fire in the kidney, and it is hot and suffocating to remove the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, makes conversion of dampness into heat; Radix Achyranthis Bidentatae is walked and can be mended, and property is kind descending, draws all medicines and goes into Liver and kidney, and can help and help invigorating the liver and kidney, benefiting essence-blood, is considered as adjuvant.
The invention has the beneficial effects as follows: show that according to modern pharmacological research most kidney-nourishing tcm drugs have estrogen-like effects, and can build up resistance, defying age; Therefore use that the Chinese medicine tonification is suffered from a deficiency of the kidney, reinforcing body resistance, be aided with the clearing heat and expelling damp detoxifcation, eliminating evil going out is the key of treatment primary disease.The present invention provides a kind of complementing estrogen and infection taken into account in the Chinese medicine for oral administration novel formulation of one for clinical;
(1) total effects situation
The criterion of therapeutical effect of reference " new Chinese medicine clinical research guideline " senile vaginitis is carried out comprehensive evaluation analysis to symptom and sign and gynecological's lab testing before and after the 31 routine patient, and 8 examples are recovery from illness as a result, 8 routine produce effects, and 11 is effectively routine, and 4 examples are invalid.Total effective rate is 87.1%, and cure-remarkable-effectiveness rate is 51.61%.
(2) symptom and sign improves situation
1. the symptom and sign total mark compares before and after the treatment:
Symptom total mark average out to 23.19+5.52 before the 31 routine patient, treatment back symptom total mark is 11.23+6.07, and credit is analysed by statistics, and P＜0.01 has significant difference.
2. each symptom and sign size scale of treatment front and back is:
(example) treatment back (example) before the treatment
Symptom P value
Do not have
(0)Gently
(1)In
(2)Heavy
(3)Do not have
(0)Gently
(1)In
(2)Heavy
(3)
Pudendum itch the pain 35 15 8 14 863＜0.05
Pudendum dry and astringent 07 13 11 9 14 53＜0.01
Profuse leukorrhea 02 15 14 8 13 73＜0.01
Leukorrhagia chromaticness 05 17 98 10 10 3＜0.01
Have a dizzy spell 11 983 15 952＞0.05
Weak 9 10 84 21 451＜0.05
Vexed 4999 15 682＜0.01
Soreness of the waist and knees 0 10 9 12 14 575＜0.01
The sexual intercourse discomfort
, pain 2 11 7 11 11 7 10 3＜0.01
3. the score of gynecological and lab testing is compared before and after the treatment:
(example) treatment back (example) before the treatment
Project P value
Do not have
(0)Gently
(1)In
(2)Heavy
(3)Do not have
(0)Gently
(1)In
(2)Heavy
(3)
Vaginal smear 088 15 0 17 95＜0.05
Leucorrhea 07 12 12 9877＜0.01
The vagina cervix uteri
Mucosa 0 10 8 13 5 13 67＜0.01
Cleannes 08 15 80 17 95＜0.05
Hormonal readiness 069 16 0 15 10 6＜0.05
PH value 04 10 17 0 11 13 7＜0.05
Brief summary
31 routine senile vaginitiss were taken woman Shu Le sheet one month, vaginal dryness, pudendum itch pain, leucorrhea amount chromaticness and have a dizzy spell, diseases such as weak vexed, soreness of the waist and knees, the uncomfortable pain of sexual intercourse levy and all have clear improvement, and wherein levy the most obvious with diseases such as vaginal dryness, leucorrhea amount chromaticness, vexed, soreness of the waist and knees, the uncomfortable pain of sexual intercourse especially.Gynecological such as treatment back vaginal smear, leucorrhea, vagina cervical mucosa, cleannes, hormonal readiness, pH value and lab testing project also have clear improvement before the treatment, and wherein leucorrhea distribution situation and vagina cervical mucosa improve the most remarkable.Symptomes complice sign, gynecological's lab testing, according to the efficacy assessment standard analysis, among the 31 routine patients, 8 example recoveries from illness, 8 routine produce effects, 11 examples are effective, and 4 examples are invalid.Total effective rate is 87.1%, and cure-remarkable-effectiveness rate is 51.61%.
Description of drawings:
Medicine production artwork of the present invention;
The specific embodiment:
Embodiment 1:
Take by weighing raw material (kilogram) by following proportioning:
Semen Cuscutae 83 Cortex Phellodendris 83 Radix Ginsengs 50 Cortex Ailanthis 60
The Rhizoma Anemarrhenae 50 Herba Polygoni Avicularis 55 Radix Achyranthis Bidentataes 33
Production method is as follows:
With Cortex Phellodendri, Radix Ginseng respectively reflux, extract,, filter and collect filtrate, again other raw material decocted, filter and collect filtrate, be condensed into the thick paste shape after filtrate is mixed and be dried to again collecting, be ground into fine powder, through granulation, granulate, be pressed into tablet, coating is packed.
Claims (4)
1, a kind of Chinese patent medicine preparation for the treatment of women's atrophic vaginitis, premature ovarian failure is made by following component: (consumption is a weight portion)
Semen Cuscutae 80-86
Cortex Phellodendri 80-86
Radix Ginseng 47-53
Cortex Ailanthi 56-66
Rhizoma Anemarrhenae 45-55
Herba Polygoni Avicularis 50-60
Radix Achyranthis Bidentatae 30-36
2, a kind of Chinese patent medicine preparation for the treatment of women's atrophic vaginitis, premature ovarian failure according to claim 1, formula optimization weight (part) ratio range is:
Semen Cuscutae 82-84
Cortex Phellodendri 82-84
Radix Ginseng 49-51
Cortex Ailanthi 59-61
Rhizoma Anemarrhenae 49-51
Herba Polygoni Avicularis 54-56
Radix Achyranthis Bidentatae 32-34
3, a kind of application for the treatment of the Chinese patent medicine preparation of women's atrophic vaginitis, premature ovarian failure, its range of application is:
Dry and astringent, scorching hot, the pruritus vulvae of treatment postmenopausal women's pudendum, sexual intercourse discomfort, pain, concurrent infection repeatedly.
4, a kind of Chinese patent medicine for the treatment of women's atrophic vaginitis, premature ovarian failure according to claim 1, its production can be made preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021588597A CN1509753A (en) | 2002-12-25 | 2002-12-25 | Chinese medicine for atrophic vaginitis and premature ovarian failure and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021588597A CN1509753A (en) | 2002-12-25 | 2002-12-25 | Chinese medicine for atrophic vaginitis and premature ovarian failure and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1509753A true CN1509753A (en) | 2004-07-07 |
Family
ID=34237198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021588597A Pending CN1509753A (en) | 2002-12-25 | 2002-12-25 | Chinese medicine for atrophic vaginitis and premature ovarian failure and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1509753A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112135621A (en) * | 2018-05-04 | 2020-12-25 | 宝洁公司 | Compositions and methods for treating vaginal atrophy |
| US11633452B2 (en) | 2018-05-04 | 2023-04-25 | The Procter & Gamble Company | Compositions and methods for treating vaginal dryness |
-
2002
- 2002-12-25 CN CNA021588597A patent/CN1509753A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112135621A (en) * | 2018-05-04 | 2020-12-25 | 宝洁公司 | Compositions and methods for treating vaginal atrophy |
| US11633452B2 (en) | 2018-05-04 | 2023-04-25 | The Procter & Gamble Company | Compositions and methods for treating vaginal dryness |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101041033A (en) | Chinese medicine for treating hepatitis B | |
| CN100586447C (en) | Chinese medicine wash liquid used for treating leucorrhea, pruritus vulvae etc. | |
| CN103417879A (en) | Drug for treatment of psoriasis | |
| CN1509753A (en) | Chinese medicine for atrophic vaginitis and premature ovarian failure and its use | |
| CN1876096A (en) | Main component of Chinese medicinal capsule for treating climacteric syndrome and preparation method thereof | |
| CN1689591A (en) | Chinese medicine for treating gynopathy and its preparing process | |
| CN1954872A (en) | Traditional Chinese medicine composite and its preparation method | |
| CN1285377C (en) | Gynecological inflammation treating medicine and its preparation method | |
| CN101019981B (en) | Chinese medicine preparation and its preparing process | |
| CN1528416A (en) | Granuless for treating psoriasis and preparing process thereof | |
| CN1357352A (en) | Prepn for treating hyperprolatin | |
| CN1308032C (en) | Pharmaceutical composition for treating dysfunctional uterine bleeding and preparation method thereof | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN110693988A (en) | Traditional Chinese medicine preparation for treating cervical HPV (human papillomavirus) infection and preparation method thereof | |
| CN100346812C (en) | Medicine for treating hyperplasia of mammary glands and fibroadenoma of breast and prepn. technique | |
| CN1242793C (en) | Precription of traditional Chinese medicine for treating gynaecological disease, its use and preparation method | |
| CN1197607C (en) | Hemostatic for treating functional uterine bleeding and hemorrhage after intrauterine contraceptive device placement and preparation method thereof | |
| CN101049349A (en) | Chinese traditional medicine preparation in use for treating liver and gall disease, and preparation method | |
| CN1116890C (en) | Medicine for treating hepatitis B | |
| CN103893621A (en) | Traditional Chinese medicament for treating senile vaginitis | |
| CN100346802C (en) | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying | |
| CN1223360C (en) | Chinese medicine for treating chest paralysis | |
| CN1088370C (en) | Tongguanshugan ointment and preparation process thereof | |
| CN1290567C (en) | Medicine for cold and pain of abdomen before and during menstruation and its preparation | |
| CN1966043A (en) | Externally applied medicament for treating hyperplasia of mammary glands and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUIZHOU HANFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIE FENGYING Effective date: 20050311 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050311 Address after: 550001 4 pen street, Guiyang Applicant after: Guizhou Hanfang Pharmaceutical Co., Ltd. Address before: 130033 Zhanjiang road in Jilin province Changchun City Economic and Technological Development Zone No. 7 (British Biotechnology Co., Ltd.) Applicant before: Xie Fengying |
|
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |